It is evident that there are numerous potential applications, including the cytosolic delivery of a range of protein-based moieties such as scFvs or nanobodies that bind to intracellular pathogenic proteins (e.g., the oncogenic RAS,63 BCR-ABL protein,64 or LMO265) or the delivery of small interfering RNA (siRNA) for the purpose of regulating transcription in cancer cells just to name two. Here, ABL1 is linked to cancer.